Bone Marrow-Derived Mesenchymal Stromal Cells: A Novel Target to Optimize Hematopoietic Stem Cell Transplantation Protocols in Hematological Malignancies and Rare Genetic Disorders

Overview

Journal J Clin Med

Specialty General Medicine

Date 2019 Dec 22

PMID 31861268

Citations 16

Authors

Stefania Crippa

Ludovica Santi

Roberto Bosotti

Giulia Porro

Maria Ester Bernardo

Affiliations

Soon will be listed here.

Abstract

Mesenchymal stromal cells (MSCs) are crucial elements in the bone marrow (BM) niche where they provide physical support and secrete soluble factors to control and maintain hematopoietic stem progenitor cells (HSPCs). Given their role in the BM niche and HSPC support, MSCs have been employed in the clinical setting to expand ex-vivo HSPCs, as well as to facilitate HSPC engraftment in vivo. Specific alterations in the mesenchymal compartment have been described in hematological malignancies, as well as in rare genetic disorders, diseases that are amenable to allogeneic hematopoietic stem cell transplantation (HSCT), and ex-vivo HSPC-gene therapy (HSC-GT). Dissecting the in vivo function of human MSCs and studying their biological and functional properties in these diseases is a critical requirement to optimize transplantation outcomes. In this review, the role of MSCs in the orchestration of the BM niche will be revised, and alterations in the mesenchymal compartment in specific disorders will be discussed, focusing on the need to correct and restore a proper microenvironment to ameliorate transplantation procedures, and more in general disease outcomes.

Citing Articles

Differential Expression of the hTERT Gene in Umbilical Cord-Derived Mesenchymal Stem Cells Cocultured with B Cell Precursor Leukemia Cell Microparticles or CD41/CD61 Platelet Microparticles.

Yari F, Ashoub M, Amirizadeh N, Nikougoftar M, Mardani Valandani H, Mirzaee Khalilabadi R Biochem Genet. 2023; 62(4):2796-2809.

PMID: 38019337 DOI: 10.1007/s10528-023-10565-9.

Mesenchymal Stromal Cells from Perinatal Tissues as an Alternative for Ex Vivo Expansion of Hematopoietic Progenitor and Stem Cells from Umbilical Cord Blood.

Bonilla X, Lara A, Llano-Leon M, Lopez-Gonzalez D, Hernandez-Mejia D, Bustos R Int J Mol Sci. 2023; 24(21).

PMID: 37958529 PMC: 10648510. DOI: 10.3390/ijms242115544.

ZIM1 Combined with Hydrogel Inhibits Senescence of Primary PαS Cells during In Vitro Expansion.

Tian Y, Hu M, Liu X, Wang X, Lu D, Li Z Int J Mol Sci. 2023; 24(11).

PMID: 37298717 PMC: 10253596. DOI: 10.3390/ijms24119766.

Hypothermic Preservation of Adipose-Derived Mesenchymal Stromal Cells as a Viable Solution for the Storage and Distribution of Cell Therapy Products.

Branco A, Tiago A, Laranjeira P, Carreira M, Milhano J, Dos Santos F Bioengineering (Basel). 2022; 9(12).

PMID: 36551011 PMC: 9774331. DOI: 10.3390/bioengineering9120805.

Development and Characterization of 3D Hybrid Spheroids for the Investigation of the Crosstalk Between B-Cell Non-Hodgkin Lymphomas and Mesenchymal Stromal Cells.

Dus-Szachniewicz K, Gdesz-Birula K, Rymkiewicz G Onco Targets Ther. 2022; 15:683-697.

PMID: 35747403 PMC: 9213039. DOI: 10.2147/OTT.S363994.

References

Takam Kamga P, Dal Collo G, Bassi G, Midolo M, Delledonne M, Chilosi M . Characterization of a new B-ALL cell line with constitutional defect of the Notch signaling pathway. Oncotarget. 2018; 9(26):18341-18350. PMC: 5915076. DOI: 10.18632/oncotarget.24836. View

Calvi L, Adams G, Weibrecht K, Weber J, Olson D, Knight M . Osteoblastic cells regulate the haematopoietic stem cell niche. Nature. 2003; 425(6960):841-6. DOI: 10.1038/nature02040. View

Simmons P, Przepiorka D, Thomas E, Torok-Storb B . Host origin of marrow stromal cells following allogeneic bone marrow transplantation. Nature. 1987; 328(6129):429-32. DOI: 10.1038/328429a0. View

Borrello I . Can we change the disease biology of multiple myeloma?. Leuk Res. 2012; 36 Suppl 1:S3-12. PMC: 3698609. DOI: 10.1016/S0145-2126(12)70003-6. View

Kovtonyuk L, Fritsch K, Feng X, Manz M, Takizawa H . Inflamm-Aging of Hematopoiesis, Hematopoietic Stem Cells, and the Bone Marrow Microenvironment. Front Immunol. 2016; 7:502. PMC: 5107568. DOI: 10.3389/fimmu.2016.00502. View

Lv F, Tuan R, Cheung K, Leung V . Concise review: the surface markers and identity of human mesenchymal stem cells. Stem Cells. 2014; 32(6):1408-19. DOI: 10.1002/stem.1681. View

Scotti C, Tonnarelli B, Papadimitropoulos A, Scherberich A, Schaeren S, Schauerte A . Recapitulation of endochondral bone formation using human adult mesenchymal stem cells as a paradigm for developmental engineering. Proc Natl Acad Sci U S A. 2010; 107(16):7251-6. PMC: 2867676. DOI: 10.1073/pnas.1000302107. View

Noronha-Matos J, Correia-de-Sa P . Mesenchymal Stem Cells Ageing: Targeting the "Purinome" to Promote Osteogenic Differentiation and Bone Repair. J Cell Physiol. 2016; 231(9):1852-61. DOI: 10.1002/jcp.25303. View

Mitsiades N, Mitsiades C, Richardson P, McMullan C, Poulaki V, Fanourakis G . Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood. 2003; 101(10):4055-62. DOI: 10.1182/blood-2002-11-3514. View

10.

McCann S, Bacigalupo A, Gluckman E, Hinterberger W, Hows J, Ljungman P . Graft rejection and second bone marrow transplants for acquired aplastic anaemia: a report from the Aplastic Anaemia Working Party of the European Bone Marrow Transplant Group. Bone Marrow Transplant. 1994; 13(3):233-7. View

11.

Ghazanfari R, Zacharaki D, Li H, Lim H, Soneji S, Scheding S . Human Primary Bone Marrow Mesenchymal Stromal Cells and Their in vitro Progenies Display Distinct Transcriptional Profile Signatures. Sci Rep. 2017; 7(1):10338. PMC: 5583257. DOI: 10.1038/s41598-017-09449-x. View

12.

Jourdan M, Tarte K, Legouffe E, BROCHIER J, Rossi J, Klein B . Tumor necrosis factor is a survival and proliferation factor for human myeloma cells. Eur Cytokine Netw. 1999; 10(1):65-70. PMC: 2025696. View

13.

Fouzia N, Edison E, Lakshmi K, Korula A, Velayudhan S, Balasubramanian P . Long-term outcome of mixed chimerism after stem cell transplantation for thalassemia major conditioned with busulfan and cyclophosphamide. Bone Marrow Transplant. 2017; 53(2):169-174. DOI: 10.1038/bmt.2017.231. View

14.

Hideshima T, Anderson K . Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer. 2002; 2(12):927-37. DOI: 10.1038/nrc952. View

15.

Kim E, Kim N, Cho S . The potential use of mesenchymal stem cells in hematopoietic stem cell transplantation. Exp Mol Med. 2013; 45:e2. PMC: 3584660. DOI: 10.1038/emm.2013.2. View

16.

Gado K, Domjan G, Hegyesi H, Falus A . Role of INTERLEUKIN-6 in the pathogenesis of multiple myeloma. Cell Biol Int. 2000; 24(4):195-209. DOI: 10.1006/cbir.2000.0497. View

17.

Redondo-Munoz J, Garcia-Pardo A, Teixido J . Molecular Players in Hematologic Tumor Cell Trafficking. Front Immunol. 2019; 10:156. PMC: 6372527. DOI: 10.3389/fimmu.2019.00156. View

18.

Robinson S, Ng J, Niu T, Yang H, McMannis J, Karandish S . Superior ex vivo cord blood expansion following co-culture with bone marrow-derived mesenchymal stem cells. Bone Marrow Transplant. 2006; 37(4):359-66. PMC: 1885539. DOI: 10.1038/sj.bmt.1705258. View

19.

Boulais M, Soudant P, Le Goic N, Quere C, Boudry P, Suquet M . Involvement of Mitochondrial Activity and OXPHOS in ATP Synthesis During the Motility Phase of Spermatozoa in the Pacific Oyster, Crassostrea gigas. Biol Reprod. 2015; 93(5):118. DOI: 10.1095/biolreprod.115.128538. View

20.

Tohda S, Nara N . Expression of Notch1 and Jagged1 proteins in acute myeloid leukemia cells. Leuk Lymphoma. 2001; 42(3):467-72. DOI: 10.3109/10428190109064603. View